MedTrace Logo

Study of Aldafermin (NGM282) in Healthy Adult Male Japanese and Non-Japanese Subjects

NCT04828265 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2022-01-31

No results posted yet for this study

Summary

This is an open-label study to assess safety, tolerability, and pharmacokinetics of Aldafermin (NGM282) in healthy adult male Japanese and non-Japanese subjects

Conditions

  • Healthy Male

Interventions

BIOLOGICAL

Aldafermin

Single dose of aldafermin

Sponsors & Collaborators

  • NGM Biopharmaceuticals, Inc

    lead INDUSTRY

Principal Investigators

  • NGM Study Director · NGM Biopharmaceuticals, Inc

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-04-13
Primary Completion
2021-07-06
Completion
2021-07-06
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04828265 on ClinicalTrials.gov